US20130150286A1 - Methods and pharmaceutical compositions for the treatment of respiratory tract infections - Google Patents

Methods and pharmaceutical compositions for the treatment of respiratory tract infections Download PDF

Info

Publication number
US20130150286A1
US20130150286A1 US13/806,796 US201013806796A US2013150286A1 US 20130150286 A1 US20130150286 A1 US 20130150286A1 US 201013806796 A US201013806796 A US 201013806796A US 2013150286 A1 US2013150286 A1 US 2013150286A1
Authority
US
United States
Prior art keywords
seq
amino acid
acid sequence
group
flagellin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/806,796
Other languages
English (en)
Inventor
Jean-Claude Sirard
Jose A. Chabalgoity
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut Pasteur de Lille
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR DE LILLE reassignment INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHABALGOITY, JOSE A., SIRARD, JEAN-CLAUDE
Publication of US20130150286A1 publication Critical patent/US20130150286A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.
  • Respiratory tract infections are common infections of the upper respiratory tract (e.g., nose, ears, sinuses, and throat) and lower respiratory tract (e.g., trachea, bronchial tubes, and lungs). Symptoms of upper respiratory tract infection include runny or stuffy nose, irritability, restlessness, poor appetite, decreased activity level, coughing, and fever.
  • Viral respiratory tract infections cause and/or are associated with sore throats, colds, croup, and the flu.
  • viruses that cause upper and lower respiratory tract infections include rhinoviruses and influenza viruses A and B.
  • Common respiratory bacterial infections cause and/or associated with, for example, whooping cough and strep throat.
  • An example of a bacterium that causes upper and lower respiratory tract infections is Streptococcus pneumoniae.
  • Streptococcus pneumoniae pneumococcus
  • Capsular polysaccharide is the main virulence factor, and its composition defines 91 serotypes of pneumococcus.
  • Certain serotypes colonize asymptomatically the human nasopharynx representing a reservoir for inter-individual transmission of the bacteria. In some individuals colonization may progress to pneumococcal pneumonia and invasive disease. In contrast, serotypes like serotype 1 are rarely associated with colonization but cause invasive infections.
  • the infection causing microorganism e.g., virus, bacterium, or fungus
  • the infection causing microorganism may be resistant or develop resistance to the administered therapeutic agent or combination of therapeutic agents.
  • microorganisms that develop resistance to administered therapeutic agents often develop pleiotropic drug or multidrug resistance, that is, resistance to therapeutic agents that act by mechanisms different from the mechanisms of the administered agents.
  • pleiotropic drug or multidrug resistance that is, resistance to therapeutic agents that act by mechanisms different from the mechanisms of the administered agents.
  • TLR2 Toll-like receptor 2
  • TLR4 TLR4
  • TLR9 Toll-like receptor 9
  • TLR signaling activates mucosal innate responses that culminate with the recruitment of phagocytes like polymorphonuclear neutrophils (PMN) and macrophages and the production of microbicidal agents.
  • PMN polymorphonuclear neutrophils
  • Modulating immunity by the activity of innate receptors is an emerging concept to elicit protective responses against infections.
  • the rationale is to promote innate responses that greatly exceed in magnitude, quality and dynamic the innate response triggered by the pathogen itself.
  • the effectiveness of TLR agonists for therapeutic treatment of infectious diseases has been demonstrated in several animal models, including models of respiratory tract infections (Brown, K. L., C. Cosseau, J. L. Gardy and R. E. Hancock 2007. Complexities of targeting innate immunity to treat infection. Trends Immunol 28:260-266; Lembo, A., M. Pelletier, R. Iyer, M. Timko, J. C. Dudda, T. E. West, C. B. Wilson, A. M. Hajjar, and S.
  • TLR5 senses bacterial flagellins that are the main constituent of flagella.
  • Various cells of the pulmonary tract including the epithelial cells express TLR5 but the modulation of the TLR5 signalling pathway has not yet been investigated for the treatment of respiratory tract infections.
  • the present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.
  • Streptococcus pneumoniae is a major cause of pneumonia in infants and the elderly. Innate defenses are essential to control pneumococcal infections and deficient responses can trigger disease in susceptible individuals.
  • flagellin can locally activate innate immunity and thereby increase the resistance to acute pneumonia.
  • Flagellin mucosal treatment improved S. pneumoniae clearance in the lungs and promoted increased survival to infection.
  • lung architecture was fully restored after the treatment of infected mice, indicating that flagellin allows the re-establishment of steady state conditions. Using a flagellin mutant that is unable to signal through TLR5, they established that TLR5 signaling is essential for protection.
  • mucosal stimulation of innate immunity by TLR5 also represents a relevant way for the treatment of respiratory tract infections.
  • microbial products like non-typeable Haemophilus influenzae lysates that are known to stimulate innate immunity by respiratory route are able to protect against various respiratory infections (Evans S E, Scott B L, Clement C G, Larson D T, Kontoyiannis D, Lewis R E, Lasala P R, Pawlik J, Peterson J W, Chopra A K, Klimpel G, Bowden G, Hook M, Xu Y, Tuvim M J, Dickey B F.
  • Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi.
  • Am J Respir Cell Mol Biol. 2010; 42:40-50 including S. pneumoniae infections (Clement C G, Evans S E, Evans C M, Hawke D, Kobayashi R, Reynolds P R, Moghaddam S J, Scott B L, Melicoff E, Adachi R, Dickey B F, Tuvim M J. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit. Care Med. 2008; 177:1322-30.).
  • Such respiratory infections include diseases that are induced by bacteria, viruses and fungi.
  • the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.
  • respiratory tract infection has its general meaning in the art and is intended to designated infections of the upper respiratory tract (e.g., nose, ears, sinuses, and throat) and lower respiratory tract (e.g., trachea, bronchial tubes, and lungs) induced by a live microorganism.
  • upper respiratory tract e.g., nose, ears, sinuses, and throat
  • lower respiratory tract e.g., trachea, bronchial tubes, and lungs
  • viruses which cause viral infections include, but are not limited to, retroviruses (e.g., human T-cell lymphotrophic virus (HTLV) types I and II and human immunodeficiency virus (HIV)), herpes viruses (e.g., herpes simplex virus (HSV) types I and II, Epstein-Barr virus, HHV6-HHV8, and cytomegalovirus), arenavirues (e.g., lassa fever virus), paramyxoviruses (e.g., morbillivirus virus, human respiratory syncytial virus, mumps, hMPV, and pneumovirus), adenoviruses, bunyaviruses (e.g., hantavirus), comaviruses, filoviruses (e.g., Ebola virus), flaviviruses (e.g., hepatitis C virus (HCV), yellow fever virus, and Japanese encephalitis virus), hepadnaviruses (
  • bacteria which cause bacterial respiratory tract infections include, but not limited to, the Aquaspirillum family, Azospirillum family, Azotobacteraceae family, Bacteroidaceae family, Bartonella species, Bdellovibrio family, Campylobacter species, Chlamydia species (e.g., Chlamydia pneumoniae ), Clostridium , Enterobacteriaceae family (e.g., Citrobacter species, Edwardsiella, Enterobacter aerogenes, Erwinia species, Escherichia coli, Hafnia species, Klebsiella species, Morganella species, Proteus vulgaris, Providencia, Salmonella species, Serratia marcescens , and Shigella flexneri ), Gardinella family, Haemophilus influenzae , Halobacteriaceae family, Helicobacter Family, Legionallaceae family, Listeria species, Methylococcaceae family, mycobacteria (
  • fungi which cause fungal infections include, but not limited to, Absidia species (e.g., Absidia corymbifera and Absidia ramosa ), Aspergillus species, (e.g., Aspergillus fiavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger , and Aspergillus terreus ), Blastomyces dermatitidis, Candida species (e.g., Candida albicans, Candida glabrala, Candida ken, Candida krusei, Candida parapsilosis, Candida pseudotropicalis, Candida quillermondii, Candida rugosa, Candida stellatoidea , and Candida tropicalis ), Coccidioides immitis, Conidiobolus species, Cryptococcus neo forms, Cunninghamella species, Histoplasma capsulatum, Mucor pusillus, Paracoccidioides brasiliensis, Pseudalle
  • the respiratory tract infection according to the invention is a bacterial respiratory tract infection, more particularly a respiratory tract infection that results from bacteria that do not have flagella.
  • bacteria that do not have flagella and cause respiratory tract infection include Streptococcus pneumoniae, Haemophilus influenzae Moraxella catarrhalis , or Mycoplasma pneumoniae .
  • the respiratory tract infection according to the invention is a pneumococcal infection.
  • TLR5 has its general meaning in the art and is intended to mean a toll-like receptor 5 of any species, but preferably a human toll-like receptor 5.
  • a TLR5 Upon activation, a TLR5 induces a cellular response by transducing an intracellular signal that is propagated through a series of signaling molecules from the cell surface to the nucleus.
  • the intracellular domain of TLR5 recruits the adaptor protein, MyD88, which recruits the serine/threonine kinases IRAK (IRAK-1 and IRAK-4).
  • IRAKs form a complex with TRAF6, which then interacts with various molecules that participate in transducing the TLR signal.
  • TLR5 signal transduction pathway components stimulate the activity of transcription factors, such as fos, jun and NF-kB, and the corresponding induction of gene products of fos-, jun- and NF-kB-regulated genes, such as, for example, IL-6, TNF- ⁇ , CXCL1, CXCL2 and CCL20.
  • transcription factors such as fos, jun and NF-kB
  • gene products of fos-, jun- and NF-kB-regulated genes such as, for example, IL-6, TNF- ⁇ , CXCL1, CXCL2 and CCL20.
  • TLR5 agonist refers to a compound (natural or not) that selectively activates or increases normal signal transduction through TLR5.
  • a TLR5 agonist can activate or increase normal signal transduction through TLR5 indirectly, for example, by modifying or altering the native conformation of TLR5 or a TLR5 ligand.
  • the activities of signalling molecules that mediate the TLR5 signal, as well as molecules produced as a result of TLR5 activation are TLR5 activities that can be observed or measured. Therefore, a TLR5 activity includes recruitment of intracellular signaling molecules, as well as downstream events resulting from TLR5 activation, such as transcription factor activation and production of immunomodulatory molecules.
  • TLR5-mediated response mediates an innate immune system response in a subject because cytokines released by TLR5-expressing cells regulate other immune system cells to promote an immune response in a subject. Therefore, as used herein the term “TLR5-mediated response” is intended to mean the ability of TLR5 agonist to induce a TLR5-mediated cellular response.
  • Exemplary TLR5-mediated cellular responses include activation of transcription factors such as fos, jun and NF-kB, production of cytokines and chemokines such as IL-6, TNF- ⁇ , CXCL1, CXCL2 and CCL20, and the stimulation of an immune response in a subject.
  • the TLR5 agonist according to the invention is a low molecular weight agonist, e.g. a small organic molecule.
  • small organic molecule refers to a molecule of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, nucleic acids, etc.). Preferred small organic molecules range in size up to about 5000 Da, more preferably up to 2000 Da, and most preferably up to about 1000 Da.
  • the TLR5 agonist according to the invention may consist in an antibody (the term including “antibody fragment”).
  • the TLR5 agonist may consist in an antibody directed against TLR5, in such a way that said antibody activates the receptor.
  • Antibodies can be raised according to known methods by administering the appropriate antigen or epitope to a host animal selected, e.g., from pigs, cows, horses, rabbits, goats, sheep, and mice, among others.
  • a host animal selected, e.g., from pigs, cows, horses, rabbits, goats, sheep, and mice, among others.
  • Various adjuvants known in the art can be used to enhance antibody production.
  • antibodies useful in practicing the invention can be polyclonal, monoclonal antibodies are preferred.
  • Monoclonal antibodies can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture. Techniques for production and isolation include but are not limited to the hybridoma technique; the human B-cell hybridoma technique; and the EBV-hybridoma technique.
  • techniques described for the production of single chain antibodies see, e.g., U.S. Pat. No. 4,946,778) can be adapted to produce anti-TLR5
  • the TLR5 agonist useful in practicing the present invention also include anti-TLR5 antibody fragments including but not limited to F(ab′)2 fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab′)2 fragments.
  • anti-TLR5 antibody fragments including but not limited to F(ab′)2 fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab′)2 fragments.
  • Fab and/or scFv expression libraries can be constructed to allow rapid identification of fragments having the desired specificity to TLR5.
  • Humanized antibodies and antibody fragments thereof can also be prepared according to known techniques.
  • “Humanized antibodies” are forms of non-human (e.g., rodent) chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region (CDRs) of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity and capacity.
  • donor antibody such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity and capacity.
  • framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence.
  • the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • the TLR5 agonist is an aptamer.
  • Aptamers are a class of molecule that represents an alternative to antibodies in term of molecular recognition.
  • Aptamers are oligonucleotide or oligopeptide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity.
  • Such ligands may be isolated through Systematic Evolution of Ligands by EXponential enrichment (SELEX) of a random sequence library, as described in Tuerk C. and Gold L., 1990.
  • the random sequence library is obtainable by combinatorial chemical synthesis of DNA. In this library, each member is a linear oligomer, eventually chemically modified, of a unique sequence.
  • Peptide aptamers consists of a conformationally constrained antibody variable region displayed by a platform protein, such as E. coli Thioredoxin A that are selected from combinatorial libraries by two hybrid methods.
  • the TLR5 agonist according to the invention is a polypeptide, and more particularly a flagellin polypeptide.
  • flagellin is intended to mean the flagellin contained in a variety of Gram-positive or Gram-negative bacterial species.
  • Non-limiting sources of flagellins include but are not limited to Escherichia , e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella , e.g., Salmonella enterica serovar Typhimurium, Serratia , e.g., Serratia marcescans , and Shigella , as well as Bacilli such as B. subtilis and B. licheniformis, Pseudomonas such as P. aeruginosa , and Streptomyces .
  • flagellin sequences and nucleotide sequences of flagellins are publically available in the NCBI Genbank, see for example Accession Nos. AAL20871, NP 310689, BAB58984, AA085383, AAA27090, NP 461698, AAK58560, YP — 001217666, YP — 002151351, YP — 001250079, AAA99807, CAL35450, AAN74969, and BAC44986.
  • flagellin sequences from these and other species are intended to be encompassed by the term flagellin as used herein. Therefore, the sequence differences between species are included within the meaning of the term.
  • flagellin polypeptide is intended to a flagellin or a fragment thereof that retains the ability to bind and activate TLR5.
  • the flagellin polypeptide according to the invention comprises the domains of flagellin involved in TLR5 signaling.
  • domain of flagellin includes naturally occurring domain of flagellin and function conservative variants thereof. “Function conservative variants” are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall conformation and function of the polypeptide, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like).
  • Amino acids other than those indicated as conserved may differ in a protein so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for example, from 70% to 99% as determined according to an alignment scheme such as by the Cluster Method, wherein similarity is based on the MEGALIGN algorithm.
  • a “function-conservative variant” also includes a polypeptide which has at least 60% amino acid identity as determined by BLAST or FASTA algorithms, preferably at least 75%, most preferably at least 85%, and even more preferably at least 90%, and which has the same or substantially similar properties or functions as the native or parent protein to which it is compared.
  • flagellin that are involved in TLR5 signaling are well known in the art, see for example Smith et al. (2003) Nat. Immunol. 4: 1247-1253 (e.g., amino acids 78-129, 135-173 and 394-444 of S. typhimurium flagellin or homologs or modified forms thereof).
  • flagellin polypeptides include but are not limited to those described in U.S. Pat. Nos. 6,585,980; 6,130,082; 5,888,810; 5,618,533; and 4,886,748; U.S. Patent Publication No. US 2003/0044429 A1; and in the International Patent Application Publications n° WO 2008097016 and WO 2009156405 which are incorporated by reference.
  • An exemplary E. coli O157:H7 flagellin is SEQ ID NO: 1.
  • An exemplary S. typhimurium flagellin is SEQ ID NO:2 or SEQ ID NO:3. Amino acid sequences at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identical to SEQ ID NO: 1 SEQ ID NO:2 or SEQ ID NO:3 can be used as flagellin polypeptides according to the invention.
  • a flagellin polypeptide of the invention may comprise: a) a N-terminal peptide having at least 90% amino acid identity with the amino acid sequence starting from the amino acid residue located at position 1 of SEQ ID NO:3 and ending at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 99 to 173 of SEQ ID NO:3; and b) a C-terminal peptide having at least 90% amino acid identity with the amino acid sequence starting at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 401 to 406 of SEQ ID NO:3 and ending at the amino acid residue located at position 494 of SEQ ID NO:3, wherein: the said N-terminal peptide is directly linked to the said C-terminal peptide, or the said N-terminal
  • said N-terminal peptide is selected from the group consisting of the amino acid sequences 1-99, 1-137, 1-160 and 1-173 of SEQ ID NO:3.
  • said C-terminal peptide is selected from the group consisting of the amino acid sequences 401-494 and 406-494 of SEQ ID NO:3.
  • said N-terminal and C-terminal peptides consist of the amino acid sequences 1-173 and 401-494 of SEQ ID NO:3, respectively.
  • said N-terminal and C-terminal peptides consist of the amino acid sequences 1-160 and 406-494 of SEQ ID NO:3, respectively.
  • said N-terminal and C-terminal peptides consist of the amino acid sequences 1-137 and 406-494 of SEQ ID NO:3, respectively.
  • said N-terminal peptide and the said C-terminal peptide are indirectly linked, one to the other, through an intermediate spacer chain consisting of a NH2-GIy-AIa-AIa-GIy-COOH (SEQ ID NO:4) peptide sequence.
  • the asparagine amino acid residue located at position 488 of SEQ ID NO:3 is replaced by a serine.
  • the flagellin polypeptide as above described comprises an additional methionine residue at the N-terminal end.
  • the flagellin polypeptide according to the invention may be recombinantly produced by recombinant cells that have been transfected with a nucleic acid that encodes its amino acid sequence and allows its effective production within the transfected cells.
  • the nucleic acid sequence encoding the flagellin polypeptide of the invention may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression.
  • a replicable vector for cloning (amplification of the DNA) or for expression.
  • Various vectors are publicly available.
  • the vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage.
  • the appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art.
  • Vector components generally include, but are not limited to, one or more of a signal sequence if the sequence is to be secreted, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques that are known to the skilled artisan.
  • the flagellin polypeptides of the invention may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or peptide.
  • a heterologous polypeptide which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or peptide.
  • the signal sequence may be a component of the vector, or it may be a part of the DNA encoding the polypeptide of interest that is inserted into the vector.
  • the signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin Il leaders.
  • the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including Saccharomyces and Kluyveromyces .alpha.-factor leaders, the latter described in U.S. Pat. No. 5,010,182), or acid phosphatase leader, the C. albicans glucoamylase leader, or the signal described in WO 90/13646.
  • yeast invertase leader alpha factor leader (including Saccharomyces and Kluyveromyces .alpha.-factor leaders, the latter described in U.S. Pat. No. 5,010,182)
  • acid phosphatase leader the C. albicans glucoamylase leader
  • mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.
  • Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses.
  • the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2.mu. plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV, or BPV) are useful for cloning vectors in mammalian cells.
  • Selection genes will typically contain a selection gene, also termed a selectable marker.
  • Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
  • suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the nucleic acid encoding the flagellin polypeptide of the invention such as DHFR or thymidine kinase.
  • An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77: 4216 (1980).
  • a suitable selection gene for use in yeast is the trp 1 gene present in the yeast plasmid YRp7.
  • the trp 1 gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85: 12 (1977).
  • Expression and cloning vectors usually contain a promoter operably linked to the nucleic acid sequence encoding the flagellin polypeptide to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the beta-lactamase and lactose promoter systems (Chang et al., Nature, 275: 615 (1978); Goeddel et al., Nature, 281:544 (1979)), alkaline phosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776), and hybrid promoters such as the tac promoter (deBoer et al., Proc.
  • promoters for use in bacterial systems also will contain a Shine-Dalgarno (S. D.) sequence operably linked to the DNA encoding the flagellin polypeptide of the invention.
  • Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem., 255: 2073 (1980)) or other glycolytic enzymes (Hess et al., J. Adv.
  • enolase such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isome
  • yeast promoters that are inducible promoters having the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657. Nucleic acid of interest transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowl pox virus (UK 2,211,504 published 5 Jul.
  • viruses such as polyoma virus, fowl pox virus (UK 2,211,504 published 5 Jul.
  • adenovirus such as Adenovirus 2
  • bovine papilloma virus such as Adenovirus 2
  • bovine papilloma virus such as avian sarcoma virus
  • cytomegalovirus such as a retrovirus
  • a retrovirus such as hepatitis-B virus
  • Simian Virus 40 SV40
  • heterologous mammalian promoters e.g., the actin promoter or an immunoglobulin promoter
  • heat-shock promoters provided such promoters are compatible with the host cell systems.
  • Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription.
  • Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, .alpha.-fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus.
  • Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.
  • the enhancer may be spliced into the vector at a position 5′ or 3′ to the sequence coding for polypeptides of interest, but is preferably located at a site 5′ from the promoter.
  • Expression vectors used in eukaryotic host cells will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5′ and, occasionally 3′, untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the flagellin polypeptide of the invention.
  • Host cells are transfected or transformed with expression or cloning vectors described herein for flagellin polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
  • the culture conditions such as media, temperature, pH, and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: A Practical Approach, M. Butler, ed. (IRL Press, 1991).
  • transfection Methods of transfection are known to the ordinarily skilled artisan, for example, CaPO4 treatment and electroporation.
  • transformation is performed using standard techniques appropriate to such cells.
  • the calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers.
  • the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed.
  • General aspects of mammalian cell host system transformations have been described in U.S. Pat. No. 4,399,216.
  • Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact, 130: 946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76: 3829 (1979).
  • other methods for introducing DNA into cells such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene or polyornithine, may also be used.
  • polycations e.g., polybrene or polyornithine
  • Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells.
  • Suitable prokaryotes include, but are not limited to, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as E. coli .
  • eubacteria such as Gram-negative or Gram-positive organisms
  • Enterobacteriaceae such as E. coli .
  • E. coli strains are publicly available, such as E. coli K12 strain MM294 (ATCC 31,446); E. coli X1776 (ATCC 31,537); E. coli strain W3110 (ATCC 27,325); and K5772 (ATCC 53,635).
  • Other suitable prokaryotic host cells include Enterobacteriaceae such as Escherichia , e.g., E.
  • Strain SIN41 of Salmonella typhimurium (fliC fljB), is particularly interesting for the production of flagellin polypeptides of the invention, since these prokaryotic host cells do not secrete any flagellins (Proc Natl Acad Sci USA. 2001; 98:13722-7). However flagellins are secreted through specialized secretion system: the so called “Type III secretion system”. Interestingly, strain SIN41 produces all components of the type III secretion system required for optimal flagellin secretion. Cloning sequence coding new flagellin peptides under fliC promoter enables secretion in large amounts of the flagellin polypeptides of interest in strain SIN41.
  • Strain W3110 is also interesting because it is a common host strain for recombinant DNA product fermentations.
  • the host cell secretes minimal amounts of proteolytic enzymes.
  • strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including E. coli W3110 strain 1A2, which has the complete genotype tonA; E. coli W3110 strain 9E4, which has the complete genotype tonA ptr3; E. coli W31 10 strain 27C7 (ATCC 55,244), which has the complete genotype tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan.sup.r; E.
  • E. coli W31 10 strain 37D6 which has the complete genotype tona ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan.sup.r; E. coli W31 10 strain 40B4, which is strain 37D6 with a non-kanamycin resistant degP deletion mutation; and an E. coli strain having mutant periplasmic protease disclosed in U.S. Pat. No. 4,946,783 issued 7 Aug. 1990.
  • coli strains MG1655, MG1655 AfimA-H or MKS12, a fliD- and -f/m>A-/-/-deleted MG1655 strain are also interesting candidates for production of recombinant flagellins as secreted proteins (Nat. Biotechnol. 2005; (4):475-81).
  • in vitro methods of cloning e.g., PCR or other nucleic acid polymerase reactions, are suitable.
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors encoding the flagellin polypeptides according to the invention.
  • Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism.
  • K. lactis MW98-8C, CBS683, CBS4574; Louvencourt et al., J. Bacterid., 737 [1983]
  • K. fragilis ATCC 12,424)
  • K. bulgaricus ATCC 16,045)
  • K. wickeramii ATCC 24,178
  • K. waltii ATCC 56,500
  • drosophilarum ATCC 36,906; Van den Berg et al., Bio/Technology, 8:135 (1990)), K. thermotolerans , and K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070; Sreekrishna et al., J. Basic Microbiol., 28: 265-278 [1988]); Candida; Trichoderma reesia (EP 244,234); Neurospora crassa (Case et al., Proc. Natl. Acad. Sci.
  • Schwanniomyces such as Schwanniomyces occidentalis (EP 394,538 published 31 Oct. 1990); and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium (WO 91/00357 published 10 Jan. 1991), and Aspergillus hosts such as A. nidulans (Ballance et al., Biochem. Biophys. Res. Commun., 112: 284-289 [1983]; Tilburn et al., Gene, 26: 205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci.
  • Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis , and Rhodotorula .
  • Suitable host cells for the expression of nucleic acid encoding flagellin polypeptide of the invention are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells.
  • Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol., 36: 59 (1977)); Chinese hamster ovary cells/ ⁇ DHFR(CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol.
  • Flagellin polypeptide of the invention may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g., TRITON-XTM. 100) or by enzymatic cleavage.
  • a suitable detergent solution e.g., TRITON-XTM. 100
  • Cells employed in expression of nucleic acid encoding the flagellin polypeptide of the invention can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell-lysing agents. It may be desired to purify the polypeptide of interest from recombinant cell proteins or polypeptides.
  • the following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; Protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the flagellin polypeptide of the invention.
  • the flagellin polypeptide is purified from the supernatant of recombinant S. Typhimurium SIN41 (fliC fljB), as disclosed in Nempont et al. (Nempont, C. C., D.; Rumbo, M.; Bompard, C.; Villeret, V.; Sirard, J. C. 2008. Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol 181:2036-2043.). In particular, Salmonella were grown in Luria-Bertani (LB) broth for 6-18 hours at 37° C. with agitation.
  • LB Luria-Bertani
  • the supernatant was filtered and saturated with 60% ammonium sulfate (Sigma Aldrich, USA).
  • the precipitated materials were recovered by centrifugation, solubilization in 20 mM Tris/HCl pH7.5 and then dialysis.
  • the proteins were further purified by successive rounds of hydroxyapatite, anion exchange, and size exlusion chromatography (Bio-Rad Laboratories, USA; GE Healthcare, Sweden). Lastly, the proteins were depleted of lipopolysaccharide (LPS) using a polymyxin B column (Pierce, USA). Using the Limulus assay (Associates of Cape Cod Inc., USA), the residual LPS concentration was determined to be less than 30 pg LPS per ⁇ g recombinant flagellin.
  • a flagellin polypeptide according to the invention may be purified by separation on an immunoaffinity chromatography substrate.
  • Said immunoaffinity chromatography substrate comprises anti-flagellin antibodies that have been immobilized thereon.
  • anti-flagellin antibodies it is intended herein antibodies that bind to either a native flagellin or to a hypervariable region-deleted flagellin, including those encompassed by the present invention.
  • the anti-flagellin antibodies consist of monoclonal antibodies, including mouse anti-flagellin antibodies.
  • a polypeptide of the invention may be synthesized through conventional techniques of chemical peptide synthesis.
  • flagellin polypeptide sequence of the invention may be produced by direct peptide synthesis using solid-phase techniques.
  • In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, with an Applied Biosystems Peptide Synthesizer (Foster City, Calif.) using manufacturer's instructions.
  • Automated synthesis may be accomplished, for instance, with an Applied Biosystems Peptide Synthesizer (Foster City, Calif.) using manufacturer's instructions.
  • polypeptide of interest may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length peptide of interest.
  • the present invention also relates to pharmaceutical compositions for use in a method for treating a respiratory tract infection comprising a TLR5 agonist according to the invention.
  • the TLR5 agonists according to the invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions.
  • pharmaceutically acceptable excipients such as a carboxylate, a carboxylate, a carboxylate, a carboxylate, a carboxylate, a carboxylate, a carboxylate, a carboxylate, a carboxysulfate, a pharmaceutically acceptable graft copolymer, or adiluent, encapsulating material or formulation auxiliary of any type.
  • composition of the invention is formulated to be compatible with its intended route of administration.
  • routes of administration include, but are not limited to, parenteral, e.g., intravenous, intradermal, subcutaneous, oral, intranasal (e.g., inhalation), transdermal (e.g., topical), transmucosal, and rectal administration.
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to human beings.
  • compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection.
  • the pharmaceutical composition of the invention is administered topically (i.e. in the respiratory tract of the subject).
  • the compositions can be formulated in the form of an ointment, cream, transdermal patch, lotion, gel, spray, aerosol, solution, emulsion, or other form well-known to one of skill in the art.
  • viscous to semi-solid or solid forms comprising a carrier or one or more excipients compatible with topical application and having a dynamic viscosity preferably greater than water are typically employed.
  • Suitable formulations include, without limitation, solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like, which are, if desired, sterilized or mixed with auxiliary agents (e.g., preservatives, stabilizers, wetting agents, buffers, or salts) for influencing various properties, such as, for example, osmotic pressure.
  • auxiliary agents e.g., preservatives, stabilizers, wetting agents, buffers, or salts
  • Other suitable topical dosage forms include sprayable aerosol preparations wherein the active ingredient, preferably in combination with a solid or liquid inert carrier, is packaged in a mixture with a pressurized volatile (e.g., a gaseous propellant, such as freon) or in a squeeze bottle.
  • a pressurized volatile e.g., a gaseous propellant, such as freon
  • humectants can also be added to pharmaceutical composition
  • the composition can be formulated in an aerosol form, spray, mist or in the form of drops.
  • prophylactic or therapeutic agents for use according to the present invention can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas).
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the method of the invention may comprise pulmonary administration, e.g., by use of an inhaler or nebulizer, of a composition formulated with an aerosolizing agent.
  • pulmonary administration e.g., by use of an inhaler or nebulizer
  • a composition formulated with an aerosolizing agent See, e.g., U.S. Pat. Nos. 6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078; and PCT Publication Nos. WO 92/19244, WO 97/32572, WO 97/44013, WO 98/31346, and WO 99/66903, each of which his incorporated herein by reference in their entirety.
  • the pharmaceutical composition of the invention is administered using Alkermes AIRTM pulmonary drug delivery technology (Alkermes, Inc., Cambridge, Mass.).
  • the invention provides a method of preventing, treating, managing, or ameliorating a respiratory tract infection or one or more symptoms thereof comprising administering a subject in need thereof with a therapeutically effective amount of a TLR5 agonist.
  • the term “subject” or “individual” to be treated is intended for a human or non-human mammal (such as a rodent (mouse, rat), a feline, a canine, or a primate) affected or likely to be affected with cancer.
  • a human or non-human mammal such as a rodent (mouse, rat), a feline, a canine, or a primate
  • the subject is a human.
  • terapéuticaally effective amount is meant for a sufficient amount of polypeptide or nucleic acid in order to treat cancer, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the polypeptide and pharmaceutical compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the polypeptide employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, the duration of the treatment; the drugs used in combination or coincidental with the specific polypeptide employed; and like factors well known in the medical arts.
  • Streptococcus pneumoniae serotype 1 (clinical isolate E1586) was obtained from the National Reference Laboratory—Ministry of Health, Republic (39).
  • Working stocks were prepared as follows. Todd Hewitt Yeast Broth (THYB) (Sigma-Aldrich, St. Louis—Mo., USA) was inoculated with fresh colonies of S. pneumoniae grown in blood-agar plates, and incubated at 37° C. until the culture reached OD 600nm of 0.7-0.9 units. Cultures were stored at ⁇ 80° C. in THYB+glycerol 12% (v/v) up to 3 months. For mouse infection, working stocks were thawed and washed with sterile physiological saline solution (saline) and diluted to the appropriate concentration. Number of bacteria in stocks was confirmed by plating serial dilutions onto blood agar plates.
  • Native flagellin from Salmonella enterica Serovar Typhimurium SIN22, or recombinant flagellins (FliC ⁇ 174-400 and FliC ⁇ 174-400/89-96* ) were prepared as previously described (27).
  • FliC ⁇ 174-400/89-96* carries aminoacids substitution (89-96) that prevents TLR5 signaling. All proteins contained low LPS amount (less than 30 pg LPS per ⁇ g, determined with the Limulus assay). In some experiments, trypsin-hydrolyzed FliC (FliC/T) was used as a control. Native FliC was heated for 5 minutes at 65° C. before use to ensure that proteins are mostly monomers.
  • mice Female BALB/c, C57BL/6J and outbred NMRI strain (6-8 weeks old) were obtained from the National Division of Veterinary Laboratories (Uruguay) or Janvier laboratories (France).
  • Female SCID mice C.B-17 SCID were obtained from Institut Pasteur de Lille breeding facilities. These mice are characterized by the lack of B and T lymphocytes and agammaglobulinaemia. Animals were maintained in individually ventilated cages and handled in a vertical laminar flow cabinet (class II A2, ESCO, Pensylvania-USA) for infection. All experiments complied with current national and institutional regulations and ethical guidelines (CHEA—Universidad de la Rep ⁇ blica, Brazil and #A59107—Institut Pasteur de Lille).
  • mice were anaesthetized by intraperitoneal (i.p.) injection of 2.2 mg Ketamine (Richmond-Vet Pharma, Bs. As.—Argentina) plus 0.11 mg Xylazine (Portinco, Montevideo—Uruguay) in a total volume of 200 ⁇ l or by inhalation of Isoflurane (Belamont, SAS, France) using an anaesthesia non-rebreathing system (DRE-Compact 150, DRE Veterinary, Louisville—US). Bacteria and flagellins were administrated onto mice's nostrils in 20 to 50 ⁇ l of saline. Mice survival was recorded daily.
  • granulocytes For depletion of granulocytes, 100 ⁇ g of anti-Gr-1 (RB6-8C5) or isotype control (HB152) were administered i.p. 24 h before i.n. challenge with S. pneumoniae (24). The anti-Gr1 injection was found to deplete 96.8 ⁇ 1.2% PMNs in Bronchoalveolar Lavages (BAL) after flagellin intranasal treatment.
  • BAL Bronchoalveolar Lavages
  • Lungs and spleen were collected at selected time points after intranasal challenge and homogenized with an UltraTurrax homogenizer (IKA-Werke, Staufen-Germany). Viable counts were determined by plating serial dilutions onto blood-agar plates.
  • UltraTurrax homogenizer IKA-Werke, Staufen-Germany
  • RNA extraction was performed according manufacturer's instructions. Prior to cDNA synthesis, 1 ⁇ g total RNA was treated with DNAse-I (Invitrogen), and first strand complementary DNA (cDNA) synthesis was carried out using random primers (Invitrogen) and M-MLV reverse transcriptase (Invitrogen). Real-time PCR was performed using QuantiTect® SYBR® Green PCR Kit (Qiagen, Hilden-Germany) in a Rotor-Gene 6000 (Corbett, Sydney-Australia) according to the following protocol: 15 min at 95° C.
  • bronchoalveolar lavages BAL sampling trachea was cannulated and 1 ml of PBS+1 mM EDTA was instilled six times and recovered by gentle aspiration; this process was repeated twice.
  • Cells were suspended in FACS-EDTA buffer (PBS, 0.1% azide, 1% bovine serum albumin from Sigma-Aldrich plus 5 mM EDTA).
  • Lung cells were isolated after collagenase/DNAse treatment as previously described (34) and filtered through a 40 ⁇ m cell strainer. Immune cells were separated in a two-layered Percoll (Sigma-Aldrich) gradient.
  • cells were suspended in 35% isotonic Percoll solution, carefully placed on top of a 70% isotonic Percoll solution and centrifuged 30 min at 2600 g and RT without brake. Top ring of cells corresponding mostly to epithelial cells was discarded and immune cells were recovered from the ring of cells closest to the 70% Percoll layer. Cells were filtered using a 100 ⁇ m cell strainer washed and stained for FACS analysis.
  • Neutrophils were identified by FSC-SSC and positive staining for PE- or Alexa Fluor 647-conjugated anti-Ly-6G (clone 1A8), PerCP-Cy5.5-conjugated anti-Ly-6C (Clone HK1.4) or PE-conjugated anti-CD11b (clone Ml/70) from BD Biosciences or BioLegend, California-USA. After fixation with PFA 4%, flow cytometry data acquisition was performed on a FACS Calibur Cytometer with CellQuest 3.3 software (BD Biosciences).
  • Lungs were fixed in 4% formalin (Sigma-Aldrich) for 24 h and then embedded in paraffin. Lung blocks were sectioned at 5 ⁇ m using a Leica microtome (Leica Microsystems, Wetzlar-Germany) and adhered to silanized slides. Hematoxylin/eosin stained sections were analyzed using a Nikon Eclipse 80i microscope and a Nikon DS-Ri1 digital camera and processed using NIS-Elements BR 3.0 software by Laboratory Imaging.
  • flagellin to control pneumococcal pneumonia was then assessed by comparing the survival of mice challenged intranasally with S. pneumoniae to mice instilled with flagellin (FliC) and S. pneumoniae .
  • FliC flagellin
  • mice were also challenged with S. pneumoniae and flagellin previously hydrolyzed with trypsin (FliC/T).
  • FliC-treated mice had a survival rate of 75%, while untreated or FliC/T-treated animals died within 3 to 4 days after challenge.
  • the protection induced by flagellin ranged from 75 to 100% between different independent experiments. Co-administration of flagellin with S.
  • pneumoniae resulted within 24 h in an 80-fold reduction of bacterial counts in the lungs as compared with animals that received S. pneumoniae alone ( FIG. 1B ).
  • flagellin could exert a protective response against pneumococcal infection when administered before and after the infection. All animals receiving flagellin intranasally 12 to 24 h before pneumococcal challenge survived, while all control mice died by day 4. Moreover, 100% protection was also achieved when flagellin was administered 24 h after the challenge. Therefore, flagellin shows prophylactic and therapeutic effects in pneumococcal pneumonia.
  • flagellin The capacity of flagellin to induce protection was also assessed in C57BL/6 and the outbred strain NMRI.
  • the MLD of S. pneumoniae serotype 1 was found to be 2 ⁇ 10 6 CFU for both strains, and flagellin-mediated protection was evaluated with 5xMLD.
  • Administration of flagellin 12 h before bacterial challenge induced 80% protection in C57BL/6 mice; similarly, 100% protection was achieved in NMRI animals when flagellin was administered 32 h to 6 h before challenge.
  • Flagellin was also protective when co-administered with S. pneumoniae in C57BL/6 and NMRI strains, although to a lower extent (40%). Altogether, these results show that flagellin treatment is protective in different mouse strains.
  • flagellin treatment modify the lung transcriptional response to pneumococcal infection.
  • Mice were challenged with S. pneumoniae or with S. pneumoniae plus flagellin as before. Another group received flagellin alone as control. Twenty four hours after treatment and infection, lungs were harvested to analyze the expression of selected genes by qRT-PCR. Administration of flagellin alone or in combination with S. pneumoniae provoked a dramatic increase in Cxcl1, Cxcl2 and Ccl20 mRNA levels as compared to pneumococcal challenge.
  • Flagellin treatment also increased expression of Tnf; although the difference was consistent, it was not statistically significant. Expression of 116 was increased in animals that were challenged and treated with flagellin but not in those that received flagellin or S.
  • Neutrophils recruitment into the airways is a landmark of both pneumococcal infection and nasal flagellin treatment and here we showed that flagellin treatment and infection activated expression of genes involved in neutrophil recruitment.
  • flagellin treatment and infection activated expression of genes involved in neutrophil recruitment.
  • BAL and lungs were collected at different time points after challenge and stained with an anti-Ly6G antibody.
  • Pneumococcal challenge induced recruitment of PMN in all animals.
  • mice treated with flagellin at the time of the challenge showed a more rapid and pronounced infiltration of PMN into the airways as compared with mice challenged with S. pneumoniae alone.
  • SCID mice deficient for antibodies, B and T cells
  • BALB/c mice immunocompetent BALB/c mice were challenged with 2 ⁇ 10 7 CFU of S. pneumoniae or S. pneumoniae with flagellin.
  • Lungs and spleen were collected 36 h after infection to determine bacterial counts.
  • Flagellin co-administration promoted clearance of bacteria in the lungs of SCID mice to a similar extent than in BALB/c mice.
  • SCID and BALB/c mice also showed lower bacterial counts in the spleen upon flagellin treatment meaning that they were able to control not only local, but also systemic infection.
  • Innate immunity is essential for controlling pneumococcal infection as shown by TLR as well as MyD88 requirement to prevent early colonization of the respiratory tract by S. pneumoniae (Albiger, B., Sandgren A., Katsuragi H., Meyer-Hoffert U., Beiter K., Wartha F., Hornef M., Normark S, and Normark B. H.2005.
  • Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice. Cell Microbiol 7:1603-1615.; Khan, A. Q., Q. Chen, Z.-Q. Wu, J. C. Paton, and C. M. Snapper. 2005.
  • flagellin upregulates the expression of proinflammatory cytokines.
  • coadministration of flagellin at the time of S. pneumoniae challenge also upregulates the expression of the PMN-specific chemokine/activator genes Cxcl1 and Cxcl2 and also Tnf and Ccl20 in the lungs whereas S. pneumoniae alone was poorly inducing these genes.
  • analysis of lung tissue sections showed a massive infiltration of cells in the peribroncheal and perivascular regions that was more pronounced in the lungs of flagellin-treated animals than in infected non-treated animals.
  • TLR5 response do not only upregulate pro-inflammatory genes but also trigger response termination. Therefore, flagellin mucosal treatment could be considered as a therapy against pneumococcal pneumonia enhancing neutrophil infiltration and concurrent limitation of inflammation that merits further evaluation in clinical trials.
  • T and B lymphocytes as well as natural antibodies may play an important role in the early control of pneumococcal pneumonia. It was showed that T lymphocytes accumulate in zones of peribroncheal inflammation at early stages of the immune response and are involved in the defense against pneumococcus since MHC class II-deficient mice lacking CD4 + T cells are more susceptible to infection compared to their wild type counterparts. It was showed that CD19-deficient mice, which have impaired development of B1a cells and natural antibody production, have increased susceptibility to pneumococcal infection. However, the results presented here show that neither T nor B cells are required for flagellin-induced local and systemic clearance of bacteria. Taken together, our results strongly suggest that changing the PMN dynamic results in effective killing of the pneumococci, even in the absence of B and T lymphocytes.
  • TLR5 signaling is required for the protection induced by flagellin.
  • TLR5 is expressed by alveolar macrophages and epithelial cells, suggesting that these resident cells may be key players in the induction of protective innate defenses against S. pneumoniae upon flagellin treatment.
  • the airway epithelium is the TLR5-activated tissue involved in chemokine production and PMN recruitment in response to flagellated bacteria.
  • murine neutrophils express TLR5, thus TLR5 signaling may also directly activate PMN and enhance their S. pneumoniae killing capacity.
  • heat killed Haemophilus influenzae can specifically increase PMN capacity to kill pneumococcus in a Nod1-dependent manner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
US13/806,796 2010-06-25 2010-06-25 Methods and pharmaceutical compositions for the treatment of respiratory tract infections Abandoned US20130150286A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2010/001911 WO2011161491A1 (en) 2010-06-25 2010-06-25 Methods and pharmaceutical compositions for the treatment of respiratory tract infections

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/001911 A-371-Of-International WO2011161491A1 (en) 2010-06-25 2010-06-25 Methods and pharmaceutical compositions for the treatment of respiratory tract infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/185,077 Continuation US10426816B2 (en) 2010-06-25 2014-02-20 Methods and pharmaceutical compositions for the treatment of respiratory tract infections

Publications (1)

Publication Number Publication Date
US20130150286A1 true US20130150286A1 (en) 2013-06-13

Family

ID=43447689

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/806,796 Abandoned US20130150286A1 (en) 2010-06-25 2010-06-25 Methods and pharmaceutical compositions for the treatment of respiratory tract infections
US14/185,077 Active 2032-03-07 US10426816B2 (en) 2010-06-25 2014-02-20 Methods and pharmaceutical compositions for the treatment of respiratory tract infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/185,077 Active 2032-03-07 US10426816B2 (en) 2010-06-25 2014-02-20 Methods and pharmaceutical compositions for the treatment of respiratory tract infections

Country Status (9)

Country Link
US (2) US20130150286A1 (pt)
EP (1) EP2585094B1 (pt)
JP (1) JP5746761B2 (pt)
KR (1) KR101768118B1 (pt)
CN (1) CN103037887B (pt)
BR (1) BR112012033121B1 (pt)
CA (1) CA2800206C (pt)
ES (1) ES2690760T3 (pt)
WO (1) WO2011161491A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008379A1 (en) * 2007-10-17 2011-01-13 The University Court Of The University Of Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3024476A1 (en) * 2013-07-26 2016-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
JP6912379B2 (ja) * 2014-12-23 2021-08-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル インフルエンザ後の細菌重感染を処置するための方法及び医薬組成物
US20170354709A1 (en) * 2014-12-24 2017-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease
WO2022098133A1 (ko) * 2020-11-06 2022-05-12 이화여자대학교 산학협력단 항바이러스 효능을 가지는 스트렙토마이세스 속 균주 및 이를 포함하는 항바이러스용 조성물
KR102540830B1 (ko) * 2020-11-06 2023-06-05 이화여자대학교 산학협력단 항바이러스 효능을 가지는 스트렙토마이세스 속 균주 및 이를 포함하는 항바이러스용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257415A1 (en) * 2002-09-03 2006-11-16 Fondation Eurov Acc Adjuvants

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0237045B1 (en) 1986-03-11 1993-10-20 Shionogi & Co., Ltd. DNA encoding flagellin and vector having the same
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DE394538T1 (de) 1989-04-28 1991-04-11 Rhein Biotech Ges. Fuer Biotechnologische Prozesse Und Produkte Mbh, 4000 Duesseldorf, De Hefezellen der schwanniomyces-gattung.
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
US5618533A (en) 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5888810A (en) 1993-11-12 1999-03-30 The United States Of America As Represented By The Secretary Of Agriculture Campylobacteri jejuni flagellin-escherichia coli LT-B fusion protein
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6211159B1 (en) 1997-04-11 2001-04-03 University Of Toronto Flagellin gene, FlaC of campylobacter
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
ATE463505T1 (de) 2001-04-20 2010-04-15 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
US8236327B2 (en) 2007-02-09 2012-08-07 Industry Foundation Of Chonnam National University Modified flagellin improved toll-like receptor 5 stimulating activity
WO2009130618A2 (en) * 2008-04-25 2009-10-29 Institute For Systems Biology Flagellin polypeptide vaccines
DK2300609T3 (da) 2008-06-25 2014-02-10 Inst Nat Sante Rech Med Hidtil ukendt flagellinbaserede immunadjuvansforbindelser samt anvendelse deraf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257415A1 (en) * 2002-09-03 2006-11-16 Fondation Eurov Acc Adjuvants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Accession number AAL20871.1 *
Burdelya et al. (Science, 2008, Vol 320: pp. 226-230) *
Intranasal Delivery (Accessed 11/21/13) *
Nempont et al. (J. Immunol 2008; 181: 2036-2043 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110008379A1 (en) * 2007-10-17 2011-01-13 The University Court Of The University Of Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
US9193770B2 (en) * 2007-10-17 2015-11-24 The University Court Of The University Of Edinburgh Immunogenic compositions containing Escherichia coli H7 flagella and methods of use thereof
US10363297B2 (en) 2007-10-17 2019-07-30 The University Court Of The University Of Edinburgh Immunogenic compositions containing Escherichia coli H7 flagella and methods of use thereof

Also Published As

Publication number Publication date
KR101768118B1 (ko) 2017-08-14
KR20140005843A (ko) 2014-01-15
CA2800206C (en) 2018-06-05
JP2013530982A (ja) 2013-08-01
BR112012033121B1 (pt) 2019-08-20
BR112012033121A2 (pt) 2016-10-11
CN103037887A (zh) 2013-04-10
ES2690760T3 (es) 2018-11-22
JP5746761B2 (ja) 2015-07-08
EP2585094A1 (en) 2013-05-01
WO2011161491A1 (en) 2011-12-29
CN103037887B (zh) 2017-11-10
US20140206601A1 (en) 2014-07-24
US10426816B2 (en) 2019-10-01
EP2585094B1 (en) 2018-08-01
CA2800206A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
US10426816B2 (en) Methods and pharmaceutical compositions for the treatment of respiratory tract infections
Nuti et al. Antimicrobial peptides: a promising therapeutic strategy in tackling antimicrobial resistance
JP6420417B2 (ja) バイオフィルムを除去するための組成物および方法
Munoz et al. Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection
JP2007504144A (ja) セリンプロテアーゼ活性阻害因子、ならびに細菌感染の治療法および組成物におけるその使用方法
JP2001510805A (ja) リソスタフィン単独含有もしくは抗生物質併用ブドウ球菌感染症治療用薬剤組成物
JP2018527933A (ja) 新規なエンドリシンポリペプチド
Underwood et al. Innate immunity and the role of defensins in otitis media
JP2014519485A (ja) コンパニオン動物および家畜におけるグラム陽性細菌を処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン
JP2018535227A (ja) 院内肺炎を予防または治療する方法
US20080095756A1 (en) Compositions Comprising Lysostaphin Variants And Methods Of Using The Same
US9598488B2 (en) Blockage of interferon-gamma for prevention of polymicrobial synergy
JP2022508619A (ja) ニューロメジンペプチドを使用して２型サイトカイン媒介性炎症を低減させる方法
US11834687B1 (en) Chimeric endolysin polypeptide
Grousd Defining Staphylococcus aureus Virulence Factors in Bacterial Pneumonia and Influenza Super-Infection
US9937234B2 (en) Compositions and methods for using and identifying antimicrobial agents
WO2023166155A1 (en) A chimeric endolysin polypeptide
WO2023166158A1 (en) A chimeric endolysin polypeptide.
GB2468803A (en) Modified serum bactericidal assay

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTITUT PASTEUR DE LILLE, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIRARD, JEAN-CLAUDE;CHABALGOITY, JOSE A.;REEL/FRAME:029883/0435

Effective date: 20121220

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SIRARD, JEAN-CLAUDE;CHABALGOITY, JOSE A.;REEL/FRAME:029883/0435

Effective date: 20121220

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION